The ASCO21 abstract recommendations

The 2021 ASCO Annual Meeting will be held virtually on June 4-8. 

Found below is the list of kidney cancer-related abstracts that will be featured at ASCO21. Don’t miss these highlights recommended by the UROONCO Editorial Board!

• Pembrolizumab versus placebo as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase 3. KEYNOTE-564 study (LBA5)
• Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC)
• Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426